Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 91

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 91
---
 net losses in
the foreseeable future. Renovaro Cube has invested significant financial resources in research and development activities, including to
develop its technology and investigational products and plan for commercial launch of its AI platform. The amount of Renovaro Cube’s
future net losses will depend, in part, on the level of Renovaro Cube’s future expenditures and its ability to generate revenue
following the commercialization of its AI platform. Moreover, Renovaro Cube’s net losses may fluctuate significantly from quarter
to quarter and year to year, such that a period-to-period comparison of Renovaro Cube’s results of operations may not
be a good indication of Renovaro Cube’s future performance.

Renovaro
Cube expects to continue to incur significant expenses and operating losses for the foreseeable future if, and as, it:

| ● | attracts, hires, and retains qualified personnel;                                                                                                        |
| ● | continues its research and development activities;                                                                                                       |
| ● | initiates and conducts additional clinical validation to support the development and commercialization of its products;                                  |
| ● | expands its technological and operating capabilities and introduces laboratory capacity as Renovaro Cube prepares for commercial scale;                  |
| ● | seeks regulatory approvals and any other marketing authorizations or clearances that may be necessary or desired for its products;                       |
| ● | establishes sales, marketing and distribution infrastructure to commercialize its products;                                                              |
| ● | acquires or in-licenses additional intellectual property and technologies;                                                                               |
| ● | makes milestone, royalty, or other payments due under any license or collaboration agreements;                                                           |
| ● | obtains, maintains, protects and enforces its intellectual property portfolio, including intellectual property obtained through license agreements;      |
| ● | provides additional infrastructure to support its continued research and development operations and any planned commercialization efforts in the future; |
| ● | as part of the combined company following the Closing, meets the requirements and demands of being a public company; and                                 |
| ● | defends against any product liability claims or other lawsuits related to its products.                                                                  |

<div align='center'>48</div>

Renovaro Cube has never generated revenue from its cancer diagnostics AI platform, and does not expect any near-term revenue to offset Renovaro Cube’s ongoing operating expenses, and may never be able to maintain profitability.

Renovaro
Cube’s ability to generate revenue from product sales and maintain profitability in the future depends on its ability to commercialize
its products. While Renovaro Cube